RheumPAC has been working to ensure that individual legislators understand what rheumatology practices and patients face when it comes to delivering high quality care to those with rheumatic diseases and advocating for policies to support affordability of care, workforce expansion, prior authorization reform and fair reimbursement levels.
In recent months, the ISC has engaged with payers to reduce administrative burden on practices and continues to advocate to the CMS for the use of complex administration codes for biologics.
Magnetic resonance imaging (MRI) is the gold standard imaging modality for the detection of sacroiliitis, a hallmark of axial spondyloarthritis (axSpA). However, the specificity of MRI for axSpA has been questioned. Renson et al. found that structural MRI-detected SI joint lesions are frequently seen in healthy individuals.
Using data from cohorts with detailed lifestyle data and lengthy follow-up, Hahn et al. demonstrated that healthy lifestyle behaviors are associated with a lower risk of developing rheumatoid arthritis (RA), concluding that a substantial proportion of RA may be preventable.
ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…
1) Obesity & Treatment Response in RA Obesity & response to advanced therapies in rheumatoid arthritis Why was this study done? There have been questions regarding whether certain therapies for rheumatoid arthritis (RA) are less effective in patients with obesity, particularly for tumor necrosis factor (TNF) inhibitors, because adipose tissue is known to generate TNF,…
The treatment and management of rheumatoid arthritis (RA) is ever evolving. Here Clifton O. Bingham, MD, discusses the application of RA guidelines, the most recent drug safety information and more.
Brendan Antiochos, MD, provided a timely update on research and treatments related to vasculitis, addressing treatments for ANCA-associated vasculitis and giant cell arteritis, COVID-19 vaccination and more.
Uzma Haque, MD, addressed the management of difficult-to-treat rheumatoid arthritis, using patient case reports to demonstrate clinical decision-making, during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.
Ana-Maria Orbai, MD, MHS, addressed the latest research into psoriatic arthritis (PsA), including a comprehensive overview of the latest FDA-approved treatments and their implications for clinical practice.